Here, we employed large-scale literature-based pathway analysis and clinical data analysis to explore the role of the PPAR-APOA1 signaling pathway in NAFLD, which may add new insights into the understanding of the NAFLD treatment. The gene discussed is APOA1; the disease is metabolic dysfunction-associated steatotic liver disease.